Inclusion Criteria:

- Patients must have cytology or biopsy-proven non-small cell lung carcinoma (NSCLC);

- Preoperative clinical stage must be 1A (T1N0), 1B(T2N0), 2A (T1N1) and 2B (T2N1) by
radiographic criteria;

- Patients must be deemed appropriate candidates for resection by the treating surgeon
and surgical assessment team;

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as
>20 mm with conventional techniques or as >10 mm with spiral CT scan;

- Age ³ 18 years;

- ECOG performance status £ 2 (Karnofsky ³ 60%; see Appendix A);

- Patients must have normal organ and marrow function as defined below:

- absolute neutrophil count ³1,500/uL

- platelets ³100,000/uL

- total bilirubin £1.5 times institutional upper limit of normal

- AST(SGOT)/ALT(SGPT) £2 times institutional upper limit of normal

- creatinine £1.5 times institutional upper limit of normal , or creatinine
clearance³50 mL/min/1.73 m2 for patients with creatinine levels above
institutional normal;

- The effects of erlotinib on the developing human fetus are unknown. For this reason,
women of childbearing potential and men must agree to use adequate
contraception (abstinence, hormonal or barrier method of birth control)
prior to study entry and for the duration of study participation. Should a
woman become pregnant or suspect she is pregnant while participating in
this study, she should inform her treating physician immediately;

- Patients on warfarin are not excluded from the trial but are required to have their
INR measured intensively during the initial stages of starting the study drug as
alterations in INR have been noted. This intensive monitoring should entail
measurements (3 X week for the first week then twice weekly for the remainder of the
trial);

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients clinically T2N1 (2B), and/or T3N0 (2B) requiring a sleeve lobectomy, and/or
chest wall resection; and tumors with higher staging;

- Patients who have received prior anticancer treatment with chemotherapy, radiotherapy
or EGFR inhibitor therapy;

- Patients who have had a previous diagnosis of cancer within 5 years are excluded
except adequately treated non-melanoma skin cancer, and carcinoma in situ of the
cervix or breast;

- Patients may not be receiving any other investigational or anticancer agents while on
study;

- History of allergic reactions to erlotinib;

- Pre-existing diarrhea ³ NCI CTC Grade 2 (4 to 6 loose stools per day) not controlled
on standard therapy;

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure or evidence of cardiac dysfunction,
unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease, poorly
controlled diabetes mellitus, clinically significant or untreated ophthalmologic
(e.g. Sjogrens etc.) or gastrointestinal conditions (e.g. Crohn's disease, ulcerative
colitis) or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study, as the effects of erlotinib on a
developing fetus are unknown. Because there is an unknown but potential risk for
adverse events in nursing infants secondary to treatment of the mother with
erlotinib, breastfeeding should be discontinued if the mother is treated with this
combination.

- HIV-positive patients receiving combination anti-retroviral therapy are excluded from
the study because of possible pharmacokinetic interactions with erlotinib.

- Active malignancy at any other site including combined small cell and non-small cell
carcinomas or a pulmonary carcinoid tumor;

- Because drugs that induce CYP3A4 enzymes have been shown to significantly reduce
plasma concentrations of erlotinib, patients with ongoing use of phenytoin,
rifampicin, carbamazepine, barbiturates, rifampicin, or St John's Wort are excluded;

- Incomplete healing from previous surgery;

- Use of any agent that decreases gastric pH, including proton pump inhibitors,
histamine-2 receptor blockers or sodium bicarbonate. Use of calcium or magnesium
based elixirs are not included;

- Concomitant use of CYP3A4 inhibitors, e.g. itraconazole, may result in increased
levels of erlotinib (TARCEVA®). This increase may be clinically relevant since
adverse experiences are related to dose and exposure.